<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2023-2-54-59</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕТОДЫ ФАРМАКОДИНАМИЧЕСКИХ ИССЛЕДОВАНИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>METHODS OF PHARMACODYNAMIC RESEARCH</subject></subj-group></article-categories><title-group><article-title>Сочетание высокоуглеводной диеты и стрептозотоцина для моделирования сахарного диабета 2 типа у крыс Вистар</article-title><trans-title-group xml:lang="en"><trans-title>Combination of a high-carbohydrate diet and streptozotoc in for modeling type 2 diabetes in Wistar rats</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0438-9108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иванов Сергей Витальевич - к. б. н., с. н. с. лаборатории психофармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Sergei V. Ivanov - PhD, Cand. Sci. (Biology), Senior Researcher at the Laboratory of Psychopharmacology</p><p>Moscow</p></bio><email xlink:type="simple">ivanov-sv-tver@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3654-6182</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Островская</surname><given-names>Р. У.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostrovskaya</surname><given-names>R. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Островская Рита Ушеровна - д. м. н., гл. н. с. лаборатории психофармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Rita U. Ostrovskaya - Dr. Sci (Med.), Chief Researcher of the Laboratory of Psychopharmacology</p><p>Moscow</p></bio><email xlink:type="simple">rita.ostrovskaya@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «НИИ фармакологии имени В.В. Закусова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBI “Zakusov Institute of Pharmacology”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>07</month><year>2023</year></pub-date><volume>0</volume><issue>2</issue><fpage>54</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Иванов С.В., Островская Р.У., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Иванов С.В., Островская Р.У.</copyright-holder><copyright-holder xml:lang="en">Ivanov S.V., Ostrovskaya R.U.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/372">https://www.pharmacokinetica.ru/jour/article/view/372</self-uri><abstract><p>Актуальность. Для проведения доклинической оценки эффективности антидиабетических лекарственных средств необходимы модели, имитирующие патогенез и основные проявления сахарного диабета (СД) у человека. Стрептозотоциновая (СТЗ) модель, получившая наиболее широкое распространение в эксперименте, не позволяет воспроизводить постадийное многофакторное развитие СД 2 типа. Цель. Разработать модель СД 2 типа с использованием высокоуглеводной диеты в сочетании с подпороговой дозой СТЗ у крыс Вистар, характеризующуюся гипергликемией и инсулинорезистентностью. Методы. Животные контрольные группы (n = 20) получали в качестве питья воду, а экспериментальной группы (n = 20) — 10 % раствор фруктозы. Через 14 дней по 10 животным из каждой группы вводили СТЗ в дозе 35 мг/кг. Уровень глюкозы в крови определяли еженедельно. Для оценки инсулинорезистентности до и после введения СТЗ проводили тест толерантности к глюкозной нагрузке. Результаты. Установлено, что содержание крыс на высокоуглеводной диете в течение двух недель ведёт к нарушению толерантности к глюкозной нагрузке, что свидетельствует об инсулинорезистентности. Введение СТЗ в подпороговой дозе 35 мг/кг животным, находящимся на стандартной диете, вызывает повышение уроня гликемии до 13,2 ммоль/л, в то время как эта же доза СТЗ на фоне высокоуглеводной диеты вызывает повышение уровня гипергликемии до 22,9 ммоль/л и усиливает инсулинорезистентность. Заключение. Синергизм высокоугледодной диеты и низких доз СТЗ позволяет получить модель сахарного диабета 2 типа, воспроизводящую не только базальную гипергликемию, но и нарушение толерантности к глюкозе, что в более полной мере соответствует процессу развития СД 2 типа у человека.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. To conduct a preclinical evaluation of the effectiveness of antidiabetic drugs, models simulating the pathogenesis and main manifestations of diabetes mellitus (DM) in humans are needed. The streptozotocin (STZ) model, which has received the most widespread use in the experiment, does not allow reproducing the stepwise multifactorial development of type 2 diabetes. Goal. To develop a model of type 2 diabetes using a high-carbohydrate diet in combination with a subthreshold dose of STZ in Wistar rats, characterized by hyperglycemia and insulin resistance. Methods. The animals of the control group (n = 20) received water as a drink, and the experimental group (n = 20) received a 10 % solution of fructose. After 14 days, 10 animals from each group were injected with STZ at a dose of 35 mg/kg. The blood glucose level was determined weekly. To assess insulin resistance, a oral glucose tolerance test was performed before and after the administration of STZ. Results. It was found that keeping rats on a high-carbohydrate diet for two weeks leads to a violation of glucose tolerance, which indicates insulin resistance. The introduction of STZ at a subthreshold dose of 35 mg/kg to animals on a standard diet causes an increase in the glycemic drop to 13.2 mmol/l, while the same dose of STZ against the background of a high-carbohydrate diet causes an increase in the level of hyperglycemia to 22.9 mmol/l and increases insulin resistance. Conclusion. The synergism of a high-carbohydrate diet and low doses of STZ makes it possible to obtain a model of type 2 diabetes mellitus that reproduces not only basal hyperglycemia, but also impaired glucose tolerance, which more fully corresponds to the process of developing type 2 diabetes in humans.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>инсулинорезистентность</kwd><kwd>доклинические исследования</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>insulin resistance</kwd><kwd>preclinical studies</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lenzen S. Animal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes. Diabetes Metab Res Rev. 2017 Oct;33(7);1–13. DOI: 10.1002/dmrr.2915.</mixed-citation><mixed-citation xml:lang="en">Lenzen S. Animal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes. Diabetes Metab Res Rev. 2017 Oct;33(7);1–13. DOI: 10.1002/dmrr.2915.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med. 2005 Apr;22(4):359–370. DOI: 10.1111/j.1464-5491.2005.01499.x.</mixed-citation><mixed-citation xml:lang="en">Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med. 2005 Apr;22(4):359–370. DOI: 10.1111/j.1464-5491.2005.01499.x.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. 2015 Sep 1;70:5.47.1–5.47.20. DOI: 10.1002/0471141755.ph0547s70.</mixed-citation><mixed-citation xml:lang="en">Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. 2015 Sep 1;70:5.47.1–5.47.20. DOI: 10.1002/0471141755.ph0547s70.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rais N, Ved A, Ahmad R, Parveen K, Gautam GK, Bari DG, Shukla KS, Gaur R, Singh AP. Model of Streptozotocin-nicotinamide Induced Type 2 Diabetes: a Comparative Review. Curr Diabetes Rev. 2022;18(8): e171121198001. DOI: 10.2174/1573399818666211117123358.</mixed-citation><mixed-citation xml:lang="en">Rais N, Ved A, Ahmad R, Parveen K, Gautam GK, Bari DG, Shukla KS, Gaur R, Singh AP. Model of Streptozotocin-nicotinamide Induced Type 2 Diabetes: a Comparative Review. Curr Diabetes Rev. 2022;18(8): e171121198001. DOI: 10.2174/1573399818666211117123358.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ostrovskaya RU, Ivanov SV, Gudasheva TA, Seredenin SB. A Novel Dipeptide NGF Mimetic GK-2 Selectively Activating the PI3K/AKT Signaling Pathway Promotes the Survival of Pancreatic β-Cells in a Rat Model of Diabetes. Acta Naturae. 2019 Jan-Mar;11(1):48–57. DOI: 10.32607/20758251-2019-11-1-48-57.</mixed-citation><mixed-citation xml:lang="en">Ostrovskaya RU, Ivanov SV, Gudasheva TA, Seredenin SB. A Novel Dipeptide NGF Mimetic GK-2 Selectively Activating the PI3K/AKT Signaling Pathway Promotes the Survival of Pancreatic β-Cells in a Rat Model of Diabetes. Acta Naturae. 2019 Jan-Mar;11(1):48–57. DOI: 10.32607/20758251-2019-11-1-48-57.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4–102. [Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4–102. (In Russ).]. DOI: 10.14341/DM12507.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4–102. [Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4–102. (In Russ).]. DOI: 10.14341/DM12507.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sasase T, Pezzolesi MG, Yokoi N, Yamada T, Matsumoto K. Animal models of diabetes and metabolic disease. J Diabetes Res. 2013;2013:281928. DOI: 10.1155/2013/281928.</mixed-citation><mixed-citation xml:lang="en">Sasase T, Pezzolesi MG, Yokoi N, Yamada T, Matsumoto K. Animal models of diabetes and metabolic disease. J Diabetes Res. 2013;2013:281928. DOI: 10.1155/2013/281928.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Тюренков И.Н., Куркин Д.В., Бакулин Д.А., Волотова Е.В., Шафеев М.А. Влияние агониста рецептора GPR119 на уровень глюкозы, массу тела и потребление пищи у животных с ожирением, обусловленным высокожировой и углеводной диетой. Проблемы эндокринологии. 2016;62(1):44–49. [Tyurenkov IN, Kurkin DV, Bakulin DA, Volotova EV, Chafeev MA. The influence of novel GPR119 agonist on body weight, food intake and glucose metabolism in obesity rats provoked high-fat and -carbohydrate diet. Problemy Endokrinologii. 2016;62(1):44–49. (In Russ).]. DOI: 10.14341/probl201662144-49.</mixed-citation><mixed-citation xml:lang="en">Тюренков И.Н., Куркин Д.В., Бакулин Д.А., Волотова Е.В., Шафеев М.А. Влияние агониста рецептора GPR119 на уровень глюкозы, массу тела и потребление пищи у животных с ожирением, обусловленным высокожировой и углеводной диетой. Проблемы эндокринологии. 2016;62(1):44–49. [Tyurenkov IN, Kurkin DV, Bakulin DA, Volotova EV, Chafeev MA. The influence of novel GPR119 agonist on body weight, food intake and glucose metabolism in obesity rats provoked high-fat and -carbohydrate diet. Problemy Endokrinologii. 2016;62(1):44–49. (In Russ).]. DOI: 10.14341/probl201662144-49.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanov SV, Ostrovskaya RU, Koliasnikova KN, et al. Low molecular weight NGF mimetic GK-2 normalizes the parameters of glucose and lipid metabolism and exhibits a hepatoprotective effect on a prediabetes model in obese Wistar rats. Clin Exp Pharmacol Physiol. 2022 Oct;49(10):1116– 1125. DOI: 10.1111/1440-1681.13693.</mixed-citation><mixed-citation xml:lang="en">Ivanov SV, Ostrovskaya RU, Koliasnikova KN, et al. Low molecular weight NGF mimetic GK-2 normalizes the parameters of glucose and lipid metabolism and exhibits a hepatoprotective effect on a prediabetes model in obese Wistar rats. Clin Exp Pharmacol Physiol. 2022 Oct;49(10):1116– 1125. DOI: 10.1111/1440-1681.13693.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hannou SA, Haslam DE, McKeown NM, Herman MA. Fructose metabolism and metabolic disease. J Clin Invest. 2018 Feb 1;128(2):545–555. DOI: 10.1172/JCI96702.</mixed-citation><mixed-citation xml:lang="en">Hannou SA, Haslam DE, McKeown NM, Herman MA. Fructose metabolism and metabolic disease. J Clin Invest. 2018 Feb 1;128(2):545–555. DOI: 10.1172/JCI96702.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009 May;119(5):1322–1334. DOI: 10.1172/JCI37385.</mixed-citation><mixed-citation xml:lang="en">Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009 May;119(5):1322–1334. DOI: 10.1172/JCI37385.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chong MF, Fielding BA, Frayn KN. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr. 2007 Jun;85(6):1511–1520. DOI: 10.1093/ajcn/85.6.1511.</mixed-citation><mixed-citation xml:lang="en">Chong MF, Fielding BA, Frayn KN. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr. 2007 Jun;85(6):1511–1520. DOI: 10.1093/ajcn/85.6.1511.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ohashi K, Munetsuna E, Yamada H, et al. High fructose consumption induces DNA methylation at PPARα and CPT1A promoter regions in the rat liver. Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):185–9. DOI: 10.1016/j.bbrc.2015.10.134.</mixed-citation><mixed-citation xml:lang="en">Ohashi K, Munetsuna E, Yamada H, et al. High fructose consumption induces DNA methylation at PPARα and CPT1A promoter regions in the rat liver. Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):185–9. DOI: 10.1016/j.bbrc.2015.10.134.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Baena M, Sangüesa G, Dávalos A, et al. Fructose, but not glucose, impairs insulin signaling in the three major insulin-sensitive tissues. Sci Rep. 2016 May 19;6:26149. DOI: 10.1038/srep26149.</mixed-citation><mixed-citation xml:lang="en">Baena M, Sangüesa G, Dávalos A, et al. Fructose, but not glucose, impairs insulin signaling in the three major insulin-sensitive tissues. Sci Rep. 2016 May 19;6:26149. DOI: 10.1038/srep26149.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Perry RJ, Camporez JG, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015 Feb 12;160(4):745–758. DOI: 10.1016/j.cell.2015.01.012.</mixed-citation><mixed-citation xml:lang="en">Perry RJ, Camporez JG, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015 Feb 12;160(4):745–758. DOI: 10.1016/j.cell.2015.01.012.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kato T, Shimano H, Yamamoto T, et al. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes. 2008 Sep;57(9):2382–2392. DOI: 10.2337/db06-1806.</mixed-citation><mixed-citation xml:lang="en">Kato T, Shimano H, Yamamoto T, et al. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes. 2008 Sep;57(9):2382–2392. DOI: 10.2337/db06-1806.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Catena C, Giacchetti G, Novello M, et al. Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension. Am J Hypertens. 2003 Nov;16(11 Pt 1):973–978. DOI: 10.1016/s0895-7061(03)01002-1.</mixed-citation><mixed-citation xml:lang="en">Catena C, Giacchetti G, Novello M, et al. Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension. Am J Hypertens. 2003 Nov;16(11 Pt 1):973–978. DOI: 10.1016/s0895-7061(03)01002-1.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014 Jan 1;6(1):a009191. DOI: 10.1101/cshperspect.a009191.</mixed-citation><mixed-citation xml:lang="en">Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014 Jan 1;6(1):a009191. DOI: 10.1101/cshperspect.a009191.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Asipu A, Hayward BE, O'Reilly J, Bonthron DT. Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes. 2003 Sep;52(9):2426–32. DOI: 10.2337/diabetes.52.9.2426.</mixed-citation><mixed-citation xml:lang="en">Asipu A, Hayward BE, O'Reilly J, Bonthron DT. Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes. 2003 Sep;52(9):2426–32. DOI: 10.2337/diabetes.52.9.2426.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006 Mar;290(3):F625–31. DOI: 10.1152/ajprenal.00140.2005.</mixed-citation><mixed-citation xml:lang="en">Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006 Mar;290(3):F625–31. DOI: 10.1152/ajprenal.00140.2005.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol. 2013 Feb 28;19(8):1166–1172. DOI: 10.3748/wjg.v19.i8.1166.</mixed-citation><mixed-citation xml:lang="en">Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol. 2013 Feb 28;19(8):1166–1172. DOI: 10.3748/wjg.v19.i8.1166.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
